Jimandin

Sitagliptin, the active ingredient in Jimandin, is a DPP‑4 inhibitor presented as a tablet for oral use. It is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus. It belongs to the class of oral hypoglycemic agents that act by increasing incretin levels, thereby enhancing glucose‑dependent insulin secretion.

GNH USA supplies Jimandin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to Good Distribution Practice and provides regulatory documentation to support import and registration in multiple jurisdictions.

Sitagliptin, marketed as Jimandin, is used in the management of type 2 diabetes mellitus, a chronic metabolic disorder.

Type 2 diabetes mellitus (monotherapy): lowers fasting and postprandial glucose levels when combined with diet and exercise. Type 2 diabetes mellitus (combination therapy): enhances glycemic control when added to metformin or other oral antidiabetics. Type 2 diabetes mellitus (inadequate control): provides additional glucose reduction for patients not achieving targets with existing regimens.

Adverse reactions reported with sitagliptin (Jimandin) span a range of frequencies and severities.

Common Side Effects: - Nasopharyngitis - Headache - Upper respiratory tract infection - Nausea - Diarrhea - Abdominal pain

Serious or Rare Side Effects: - Pancreatitis - Severe allergic reactions (e.g., Stevens‑Johnson syndrome) - Joint pain - Hepatic enzyme elevation - Severe hypoglycemia, especially with insulin or sulfonylureas - Bullous pemphigoid

When prescribing sitagliptin, clinicians should consider several safety aspects.

Renal function: assess creatinine clearance before initiating and adjust dose if needed. Hepatic impairment: use with caution; monitor liver enzymes. Elderly patients: monitor for hypoglycemia, especially when combined with insulin or sulfonylureas. Concurrent sulfonylureas or insulin: increased risk of hypoglycemia; consider dose reduction. Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk. Store at ambient temperature: keep in original container, protect from moisture and light.

Sitagliptin may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Insulin therapy: may cause severe hypoglycemia. - Sulfonylureas (e.g., glipizide): heightened hypoglycemia risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase sitagliptin exposure.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce sitagliptin plasma levels, decreasing efficacy. - Diuretics (e.g., thiazides): may affect glucose control; monitor blood sugar. - ACE inhibitors or ARBs: monitor renal function and potassium when combined.